Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,065.00
Bid: 4,060.00
Ask: 4,061.00
Change: 38.00 (0.94%)
Spread: 1.00 (0.025%)
Open: 4,049.00
High: 4,077.00
Low: 4,022.00
Prev. Close: 4,027.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Statement

28 Oct 2010 07:00

RNS Number : 1272V
Croda International PLC
28 October 2010
 



28 October 2010

 

 

Croda International Plc

 

Third Quarter Trading Statement

 

Commenting on trading for the quarter ended 30 September 2010, Martin Flower, Chairman of Croda International Plc, said:

 

"I am pleased to report continued strong progress in the third quarter, driven by significant sales growth building on a robust 2009 performance.

 

For the three months ended 30 September 2010, Group sales from continuing operations increased 18.6% to £255.3m (2009: £215.2m). Sales volumes increased by 12.1% compared to 2009. More importantly the two year volume trend versus 2008 (which takes out most of the effect of the recession) is showing increasing momentum:

 

2010 v 2009

2009 v 2008

2 year growth

Q1:

+30%

-28%

-6%

Q2:

+26%

-24%

-4%

Q3:

+12%

-6%

+5%

 

Quarter three is normally a quieter trading period than either of the first two quarters. Operating profit from continuing operations increased 47.1% to £48.7m (2009: £33.1m). Interest costs fell, due to lower borrowings, resulting in continuing pre-tax profit increasing 56.8% to £47.5m (2009: £30.3m).

 

Year-to-date, the pre-tax profit from continuing operations is up 87.6% at £143.7m (2009: £76.6m).

 

In quarter three Consumer Care has continued to trade robustly with big increases in sales (+15.4%) and operating profit (+32.5%) and improved margins versus the corresponding quarter in 2009. All business areas were ahead of 2009 with Crop Care delivering a particularly strong performance.

 

In Industrial Specialities the third quarter trading improvement versus 2009 is more marked with sales and profits up 22.1% and 89.4% respectively. Again, all business areas were ahead of 2009 in both sales and profits.

 

The quarter also saw a significant reduction in net debt with a cash inflow of £32.2m before adverse currency translation of £3.2m, bringing the year-to-date figure to £47.4m with favourable currency translation taking the total net debt reduction to £47.8m for the nine months. At the end of September, net debt stood at £240.7m.

 

Croda continues to trade strongly and we expect to report further year on year progress in the final quarter of 2010 and into 2011."

 

For further information please contact:

 

Mike Humphrey

Group Chief Executive

01405 860551

Sean Christie

Group Finance Director

01405 860551

Charlie Armitstead

Financial Dynamics

020 7269 7176

 

 

The company will host a conference call for analysts at 8.00am today.

 

Please dial +44 (0)1452 542 303 and quote "Croda International" to gain access to the call.

 

 

 

£m

Q3

9 months

2010

2009

2010

2009

Consumer Care

128.2

111.1

392.5

343.5

Industrial Specialities

127.1

104.1

379.9

280.1

Continuing turnover

255.3

215.2

+18.6%

772.4

623.6

+23.9%

Consumer Care

32.6

24.6

103.8

77.4

Industrial Specialities

16.1

8.5

45.7

9.4

Continuing operating profit

48.7

33.1

+47.1%

149.5

86.8

+72.2%

Operating margin

19.1%

15.4%

19.4%

13.9%

Interest

(1.2)

(2.8)

(5.8)

(10.2)

Continuing pre tax profit

47.5

30.3

+56.8%

143.7

76.6

+87.6%

 

Analysis of Q3 turnover uplift

Price/mix

+4.4%

Volume

+12.1%

Currency translation

+2.1%

Continuing turnover increase

+18.6%

 

 

 

Industrial Specialities turnover for 2009 and 2010 restated to include final adjustments relating to the discontinued Emmerich business.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAKEXADNEFFF
Date   Source Headline
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:04 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.